InvestorsHub Logo
Followers 74
Posts 1863
Boards Moderated 0
Alias Born 04/30/2011

Re: cty post# 782

Thursday, 04/24/2014 4:22:36 PM

Thursday, April 24, 2014 4:22:36 PM

Post# of 3683
Thanks for that! Here is pr from Catapults site: https://ct.catapult.org.uk/news-page/-/asset_publisher/tDqW3YjSO45r/content/cell-therapy-catapult-to-work-with-athersys-on-projects-to-advance-european-development-of-multistem%C2%AE-therapy;jsessionid=E82846A6EED02BB7322D94E370EC3063.3?redirect=%2F


Cell Therapy Catapult will undertake a European market access assessment for the MultiStem product which considers factors such as data requirements for evidence-based decision making, payers' value perceptions and pricing benchmarks.

Keith Thompson, CEO of the Cell Therapy Catapult, said, 'Understanding market dynamics and reimbursement issues is a crucial part of the development of cell therapies such as MultiStem. We are pleased to be using our expertise in this analysis for Athersys, and look forward to helping other UK and international cell therapy organisations move their products towards the market."

'We are happy to be working with the Cell Therapy Catapult, which is widely recognised as a leading European centre for the development of cell therapies, on this and other important projects', commented Gil Van Bokkelen, Chairman and CEO of Athersys. 'The market access assessment will provide information that is important to our further development of MultiStem in Europe and beyond.'